Up regulated expression of tumour necrosis factor α converting enzyme in peripheral monocytes of patients with early systemic sclerosis

Background: Systemic sclerosis (SSc) is accompanied by abnormalities in humoral and cellular immune systems. Objective: To determine the genes specifically expressed in the immune system in SSc by analysis of the gene expression profile of peripheral blood mononuclear cells (PBMC) from patients with SSc, including those treated with haematopoietic stem cell transplantation (HSCT). Additionally, to investigate the clinical significance of the up regulation of tumour necrosis factor α (TNFα) converting enzyme (TACE). Methods: PBMC from patients with SSc (n = 23) and other autoimmune diseases (systemic lupus erythematosus (SLE, n = 16), rheumatoid arthritis (RA, n = 29)), and from disease-free controls (n = 36) were examined. Complementary DNA arrays were used to evaluate gene expression of PBMC, in combination with real time quantitative polymerase chain reactions. TACE protein expression in PBMC was examined by fluorescence activated cell sorter (FACS). Results: In patients with SSc 118 genes were down regulated after HSCT. Subsequent comparative analysis of SSc without HSCT and healthy controls indicated SSc-specific up regulation for three genes: monocyte chemoattractant protein-3 (p = 0.0015), macrophage inflammatory protein 3α (p = 0.0339), and TACE (p = 0.0251). In the FACS analysis, TACE protein was mainly expressed on CD14+ monocytes both in patients with SSc and controls. TACE expression on CD14+ cells was significantly increased in patients with early SSc (p = 0.0096), but not in those with chronic SSc, SLE, or RA. TACE protein levels in SSc monocytes correlated with the intracellular CD68 levels (p = 0.0016). Conclusions: Up regulation of TACE expression was a unique profile in early SSc, and may affect the function of TNFα and other immunoregulatory molecules.

[1]  R. Silver,et al.  Cytokine concentrations in bronchoalveolar lavage fluid of patients with systemic sclerosis. , 1997, Arthritis and rheumatism.

[2]  M. Gruschwitz,et al.  Up-regulation of class II major histocompatibility complex and intercellular adhesion molecule 1 expression on scleroderma fibroblasts and endothelial cells by interferon-gamma and tumor necrosis factor alpha in the early disease stage. , 1997, Arthritis and rheumatism.

[3]  D. Wallach,et al.  MAP3K-related kinase involved in NF-KB induction by TNF, CD95 and IL-1 , 1997, Nature.

[4]  V. Milošević,et al.  Chronic Estradiol Exposure Modulates Thyroid Structure and Decreases T4 and T3 Serum Levels in Middle-Aged Female Rats , 2005, Hormone Research in Paediatrics.

[5]  B. White,et al.  The role of chemokines in the pathogenesis of scleroderma , 2003, Current opinion in rheumatology.

[6]  C. Platsoucas,et al.  Is systemic sclerosis an antigen-driven T cell disease? , 2004, Arthritis and rheumatism.

[7]  N. Kamatani,et al.  Tumor necrosis factor-alpha (TNF-alpha) converting enzyme contributes to production of TNF-alpha in synovial tissues from patients with rheumatoid arthritis. , 2001, The Journal of rheumatology.

[8]  S. Sa,et al.  CTGF and SMADs, Maintenance of Scleroderma Phenotype Is Independent of SMAD Signaling* , 2001, The Journal of Biological Chemistry.

[9]  M. Jinnin,et al.  Antagonistic Effects of TNF-α on TGF-β Signaling Through Down-Regulation of TGF-β Receptor Type II in Human Dermal Fibroblasts1 , 2003, The Journal of Immunology.

[10]  M. Lambert,et al.  Cloning of a disintegrin metalloproteinase that processes precursor tumour-necrosis factor-α , 1997, Nature.

[11]  P. Allavena,et al.  IL‐10 prevents the differentiation of monocytes to dendritic cells but promotes their maturation to macrophages , 1998, European journal of immunology.

[12]  Michael H. Rabinowitz,et al.  Inhibition of tumor necrosis factor-alpha (TNF-alpha) production and arthritis in the rat by GW3333, a dual inhibitor of TNF-alpha-converting enzyme and matrix metalloproteinases. , 2001, The Journal of pharmacology and experimental therapeutics.

[13]  H. Paulus,et al.  Muscle disease in progressive systemic sclerosis: diagnostic and therapeutic considerations. , 1978, Arthritis and rheumatism.

[14]  J. Varga.  Scleroderma and Smads: dysfunctional Smad family dynamics culminating in fibrosis. , 2002, Arthritis and rheumatism.

[15]  George Kollias,et al.  The transmembrane form of tumor necrosis factor is the prime activating ligand of the 80 kDa tumor necrosis factor receptor , 1995, Cell.

[16]  K. Takehara.  Hypothesis: pathogenesis of systemic sclerosis. , 2003, The Journal of rheumatology.

[17]  R. Abagyan,et al.  TNF-α Convertase Enzyme from Human Arthritis-Affected Cartilage: Isolation of cDNA by Differential Display, Expression of the Active Enzyme, and Regulation of TNF-α , 1998, The Journal of Immunology.

[18]  R. Wise,et al.  Occurrence of an activated, profibrotic pattern of gene expression in lung CD8+ T cells from scleroderma patients. , 2003, Arthritis and rheumatism.

[19]  B. Seed,et al.  Regulated commitment of TNF receptor signaling: a molecular switch for death or activation. , 1999, Immunity.

[20]  T. Medsger,et al.  Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. , 1988, The Journal of rheumatology.

[21]  S. Jimenez,et al.  Oligoclonal T Cell Expansion in the Skin of Patients with Systemic Sclerosis1 , 2002, Journal of Immunology.

[22]  A. Silman,et al.  European multicentre study to define disease activity criteria for systemic sclerosis.* I. Clinical and epidemiological features of 290 patients from 19 centres , 2001, Annals of the rheumatic diseases.

[23]  T. Koike,et al.  High-dose immunoablative therapy with hematopoietic stem cell support in the treatment of severe autoimmune disease: current status and future direction. , 2002, Internal medicine.

[24]  M. Asaka,et al.  Up-regulated Smad5 Mediates Apoptosis of Gastric Epithelial Cells Induced by Helicobacter pylori Infection* , 2003, The Journal of Biological Chemistry.

[25]  M. Schmuth,et al.  Expression of the C‐C chemokine MIP‐3α/CCL20 in human epidermis with impaired permeability barrier function , 2002, Experimental dermatology.

[26]  L. Mouthon,et al.  New insights into the pathogenesis of systemic sclerosis. , 2003, Autoimmunity reviews.

[27]  A. Gratwohl,et al.  Haemopoietic stem cell transplantation in the treatment of severe autoimmune diseases 2000 , 2001, Annals of the rheumatic diseases.

[28]  D. Furst,et al.  The prevalence of conduction defects and cardiac arrhythmias in progressive systemic sclerosis. , 1981, Annals of internal medicine.

[29]  D. Abraham,et al.  Monocyte chemoattractant protein 3 as a mediator of fibrosis: Overexpression in systemic sclerosis and the type 1 tight-skin mouse. , 2003, Arthritis and rheumatism.

[30]  A. Freemont,et al.  Sequential dermal microvascular and perivascular changes in the development of scleroderma , 1992, The Journal of pathology.

[31]  R. Charter,et al.  The nature of arthritis pain. , 1985, British journal of rheumatology.

[32]  Monika Bzowska,et al.  Structure and functions of tumor necrosis factor-converting enzyme , 2003 .

[33]  S. Nagata,et al.  Membrane-anchored CD40 is processed by the tumor necrosis factor-alpha-converting enzyme. Implications for CD40 signaling. , 2003, The Journal of biological chemistry.

[34]  P. Scheurich,et al.  The type 1 receptor (CD120a) is the high-affinity receptor for soluble tumor necrosis factor. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[35]  P Ramond,et al.  Molecular cloning of the MCP-3 chemokine gene and regulation of its expression. , 1993, European cytokine network.

[36]  S. Nagata,et al.  Membrane-anchored CD40 Is Processed by the Tumor Necrosis Factor-α-converting Enzyme , 2003, Journal of Biological Chemistry.

[37]  J. Alcamí,et al.  Chemokine expression by systemic sclerosis fibroblasts: abnormal regulation of monocyte chemoattractant protein 1 expression. , 2001, Arthritis and rheumatism.

[38]  K. Sullivan,et al.  Phase I/II trial of autologous stem cell transplantation in systemic sclerosis: procedure related mortality and impact on skin disease , 2001, Annals of the rheumatic diseases.

[39]  Nicole Nelson,et al.  A metalloproteinase disintegrin that releases tumour-necrosis factor-α from cells , 1997, Nature.

[40]  James F. Fries,et al.  Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. , 1980, Arthritis and rheumatism.

[41]  M. Hochberg,et al.  Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. , 1997, Arthritis and rheumatism.

[42]  D. Launay.  [Hematopoietic stem cell transplantation in the treatment of severe autoimmune diseases]. , 2001, La Revue de medecine interne.

[43]  N Rowell,et al.  Systemic sclerosis. , 1968, British medical journal.

[44]  U. Haustein,et al.  In situ expression and serum levels of tumor necrosis factor-alpha receptors in patients with early stages of systemic sclerosis. , 1997, The Journal of rheumatology.

[45]  F. Breedveld,et al.  Autologous stem cell transplantation in the treatment of systemic sclerosis: report from the EBMT/EULAR Registry , 2004, Annals of the rheumatic diseases.

[46]  S. Sa,et al.  Tumor Necrosis Factor α Suppresses the Induction of Connective Tissue Growth Factor by Transforming Growth Factor-β in Normal and Scleroderma Fibroblasts* , 2000, The Journal of Biological Chemistry.

[47]  L. Tartaglia,et al.  Ligand passing: the 75-kDa tumor necrosis factor (TNF) receptor recruits TNF for signaling by the 55-kDa TNF receptor. , 1993, The Journal of biological chemistry.

[48]  Furst De,et al.  Hypothesis for the pathogenesis of systemic sclerosis. , 1997 .

[49]  S. Jimenez,et al.  Mononuclear cellular infiltrates in clinically involved skin from patients with systemic sclerosis of recent onset predominantly consist of monocytes/macrophages. , 1995, Pathobiology : journal of immunopathology, molecular and cellular biology.

[50]  A. Saalbach,et al.  Chemokine release from activated human dermal microvascular endothelial cells – implications for the pathophysiology of scleroderma? , 2000, Archives of Dermatological Research.

[51]  齊藤 恵里子.  CD19-dependent B lymphocyte signaling thresholds influence skin fibrosis and autoimmunity in the tight-skin mouse , 2003 .

[52]  Monika Bzowska,et al.  Structure and functions of tumor necrosis factor-alpha converting enzyme. , 2003, Acta biochimica Polonica.

[53]  S. Mercurio,et al.  Replication and phenotypic expression of control and scleroderma human fibroblasts: responses to growth factors. , 1982, Proceedings of the National Academy of Sciences of the United States of America.

[54]  A. Masi.  Preliminary criteria for the classification of systemic sclerosis (scleroderma). , 1980, Bulletin on the rheumatic diseases.

[55]  J F Fries,et al.  The 1982 revised criteria for the classification of systemic lupus erythematosus. , 1982, Arthritis and rheumatism.

[56]  S. Ropele,et al.  TACE mRNA expression in peripheral mononuclear cells precedes new lesions on MRI in multiple sclerosis , 2002, Multiple sclerosis.

[57]  David C. Lee,et al.  An essential role for ectodomain shedding in mammalian development. , 1998, Science.

[58]  M. Liang,et al.  The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. , 1988, Arthritis and rheumatism.

[59]  Y. Mizui,et al.  cDNA cloning of mouse tumor necrosis factor-alpha converting enzyme (TACE) and partial analysis of its promoter. , 1999, Gene.

[60]  S. Schabel,et al.  High resolution computed tomography in early scleroderma lung disease. , 1991, The Journal of rheumatology.

[61]  R. Burt,et al.  The promise of hematopoietic stem cell transplantation for autoimmune diseases , 2003, Bone Marrow Transplantation.

[62]  R. Abagyan,et al.  TNF-alpha convertase enzyme from human arthritis-affected cartilage: isolation of cDNA by differential display, expression of the active enzyme, and regulation of TNF-alpha. , 1998, Journal of immunology.

[63]  M. Xiong,et al.  Systemic Sclerosis (Scleroderma): Specific Autoantigen Genes Are Selectively Overexpressed in Scleroderma Fibroblasts1 , 2001, The Journal of Immunology.

[64]  W. Seeger,et al.  In situ localization of TNFα/β, TACE AND TNF receptors TNF-R1 and TNF-R2 in control and LPS-treated lung tissue , 2003 .

[65]  V. Steen.  Scleroderma renal crisis. , 2003, Rheumatic diseases clinics of North America.